Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information and the Shift to Occupational Context

The legacy heritage of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad domain, the dissemination of knowledge regarding osteoporosis management and the use of bisphosphonates like Fosamax has been a routine part of patient education. Historically, such information focused on bone density maintenance and fracture prevention, reflecting a conventional health promotion perspective. As the scope of health information evolves, attention has increasingly turned toward the occupational contexts in which pharmaceutical agents are manufactured, handled, and distributed. This shift from a purely clinical or consumer-oriented framework to one that considers workplace exposure represents a natural progression in the field.

Bridging General Health Literacy and Occupational Exposure Concerns

The transition from general health literacy to occupational health concerns requires careful consideration of how substances are encountered in professional settings, distinct from their intended therapeutic use. In the mass production environment, workers may come into contact with active pharmaceutical ingredients through inhalation, dermal absorption, or inadvertent ingestion during manufacturing processes. This occupational exposure pathway raises distinct questions about potential health risks that differ from those experienced by patients taking prescribed doses. The bridge between general health information and occupational exposure concern thus lies in recognizing that the same compounds, when encountered in industrial settings, may present unique risk profiles that warrant dedicated investigation.

Fosamax and Osteonecrosis of the Jaw: Clinical Evidence and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures. Clinical presentation of ONJ typically involves delayed healing after tooth extraction, local infection, or spontaneous bone exposure. The condition is generally associated with invasive dental procedures, such as tooth extraction, dental implants, or boney surgery, as well as local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis relies on clinical examination and imaging, with multiscale characterization of jawbone providing comprehensive information to understand jawbone-specific responses to bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Duration of Exposure

The mechanistic pathways linking Fosamax to ONJ involve bisphosphonate accumulation in bone, particularly in the jaw, due to high bone turnover in that region. This accumulation can suppress osteoclast activity, impair bone remodeling, and reduce blood supply, leading to bone necrosis. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4 'Osteonecrosis of the Jaw,' noting that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset, excluding other causes such as cancer or concomitant therapies, and evaluating risk factors like dental procedures. The evidence supports a causal link, as ONJ risk increases with longer exposure and diminishes after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). Patients who develop severe symptoms should discontinue Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Overall, while ONJ is a rare adverse effect, the risk is elevated with prolonged Fosamax use, and adequate warnings are provided in the drug label.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The risk increases with longer use, especially beyond 2-3 years, and is higher in patients undergoing dental procedures. Studies show that ONJ risk is threefold higher after 2-3 years and eightfold higher after 10 years of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ from Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and what are the symptoms?

ONJ presents as exposed, non-healing bone in the jaw, often after dental procedures or spontaneously. Diagnosis is based on clinical examination and imaging. Multiscale characterization of jawbone can provide comprehensive information (https://pubmed.ncbi.nlm.nih.gov/40345077/). Symptoms include pain, swelling, infection, and delayed healing.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.